Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
Selected a contract manufacturer for commercial launch of M207 Completed first required data set in long-term safety study of M207 Appointed Greg Kitchener as Chief Financial Officer FREMONT,Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update
FREMONT, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET .
View HTML
Toggle Summary Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study
FREMONT, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 evaluable subjects have completed their six month visit in the M207-ADAM study (the "Study"), a
View HTML
Toggle Summary Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective
Live webcast of the event available for analysts and investors FREMONT, Calif. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic
View HTML
Toggle Summary Zosano Appoints New Chief Financial Officer
Seasoned financial and operational executive further strengthens management team FREMONT, Calif. , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver
View HTML
Toggle Summary Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207
FREMONT, Calif. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology,
View HTML
Toggle Summary Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment
Zosano obtains lease financing for the purchase of capital equipment for the scale up and planned commercialization of M207 FREMONT, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Zosano Pharma Completes Manufacture of M207 Registration Batches
FREMONT, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied
View HTML
Toggle Summary Zosano Pharma to Present Phase 3 Safety Study Update for ADAM™ Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference
FREMONT, Calif. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology
View HTML
Toggle Summary Zosano Pharma and Collaborators to Present Efficacy Data for M207 in the Treatment of Migraine at the 17th Biennial Migraine Trust International Symposium (MTIS)
FREMONT, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied
View HTML